UBS Group’s NKGen Biotech, Inc. Common Stock NKGN Stock Holding History

UBS Group’s Portfolio NKGN Stock Details NKGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-763	Closed	-$500	–	10975
2024 Q4	$500	Sell	763 -13,883	-95%	-$5.66K	﹤0.01%	9446
2024 Q3	$5.54K	Sell	14,646 -29,171	-67%	-$25.9K	﹤0.01%	8045
2024 Q2	$55.6K	Buy	43,817 +32,728	+295%	+$45.7K	﹤0.01%	6610
2024 Q1	$21K	Buy	+11,089	New	+$21.3K	﹤0.01%	6911
2023 Q2	–	Sell	-590	Closed	-$5.98K	–	9840
2023 Q1	$5.98K	Sell	590 -1,150	-66%	-$11.6K	﹤0.01%	7970
2022 Q4	$17.3K	Hold	1,740	–	–	﹤0.01%	7844
2022 Q3	$17K	Buy	+1,740	New	+$17K	﹤0.01%	7628

Other funds holding NKGN

Diametric Capital Boston, Massachusetts $385M AUM 31.69% 1-Year Est. Return

UOC

University of Chicago Chicago, Illinois $323M AUM 14.1% 1-Year Est. Return

FTUS

Flow Traders U.S. New York $3.16B AUM 19.52% 1-Year Est. Return

UBS Group's NKGN Position: Q1 2025 in Review

UBS Group sold out of NKGen Biotech, Inc. Common Stock (NKGN) in Q1 2025, closing a stake of 763 shares — an estimated $500 sold.

UBS Group first reported a position in NKGN in Q3 2022 and held it in 7 quarters. The position peaked at $55.6K in Q2 2024. 3 funds tracked by Wall St. Rank hold NKGN as of Q1 2025.

UBS Group reported no remaining NKGen Biotech, Inc. Common Stock position as of Q1 2025 after selling out during the quarter.
UBS Group sold 763 NKGen Biotech, Inc. Common Stock shares in Q1 2025, an estimated $500.
UBS Group first reported a position in NKGen Biotech, Inc. Common Stock in Q3 2022 and held it in 7 quarters.
UBS Group's NKGen Biotech, Inc. Common Stock position peaked at $55.6K in Q2 2024.
3 funds tracked by Wall St. Rank held NKGen Biotech, Inc. Common Stock as of Q1 2025.

Based on UBS Group's 13F filing for Q1 2025, filed 13 May 2025.